Notoginsenoside Ft1

Synonyms: 三七皂苷FT1
Notoginsenoside Ft1 是一种口服有效的生物活性皂苷,它通过抑制 PI3K/AKT/mTOR 信号通路、激活 p38 MAPK 和 ERK1/2 信号通路并增加 CD8+ T 细胞比例,诱导多种癌细胞凋亡 (apoptosis) 和溶酶体细胞死亡,同时促进血管生成;通过激活内皮细胞中的糖皮质激素受体 (GR) 和雌激素受体 β (ERβ) 引起血管舒张;通过激活由 P2Y12 受体介导的信号网络,增加细胞内 Ca2+ 积累、降低 cAMP 水平并促进血小板聚集,从而发挥促凝血作用;通过激活 TGR5 受体抑制肾小管上皮细胞铁死亡 (ferroptosis),从而显示出肾脏保护作用;并可作为 TGR5 激动剂和 FXR 拮抗剂抵抗肥胖和胰岛素抵抗。
产品编号: MS-A69242 纯度: 99.49% CAS No.: 155683-00-4 分子式: C47H80O17 分子量: 917.13
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Notoginsenoside Ft1 是一种口服有效的生物活性皂苷,它通过抑制 PI3K/AKT/mTOR 信号通路、激活 p38 MAPK 和 ERK1/2 信号通路并增加 CD8+ T 细胞比例,诱导多种癌细胞凋亡 (apoptosis) 和溶酶体细胞死亡,同时促进血管生成;通过激活内皮细胞中的糖皮质激素受体 (GR) 和雌激素受体 β (ERβ) 引起血管舒张;通过激活由 P2Y12 受体介导的信号网络,增加细胞内 Ca2+ 积累、降低 cAMP 水平并促进血小板聚集,从而发挥促凝血作用;通过激活 TGR5 受体抑制肾小管上皮细胞铁死亡 (ferroptosis),从而显示出肾脏保护作用;并可作为 TGR5 激动剂和 FXR 拮抗剂抵抗肥胖和胰岛素抵抗。

生物实验数据

生物活性 Notoginsenoside Ft1 is an orally effective bioactive saponin that induces apoptosis and lysosomal cell death in multiple cancer cells and promotes angiogenesis by inhibiting the PI3K/AKT/mTOR signaling pathway, activating the p38 MAPK and ERK1/2 signaling pathways, and increasing the proportion of CD8+ T cells; causes vasodilation by activating glucocorticoid receptor (GR) and estrogen receptor β (ERβ) in endothelial cells; exerts procoagulant effects by activating a P2Y12 receptor-mediated signaling network, increasing intracellular Ca2+ accumulation, decreasing cAMP levels, and promoting platelet aggregation; exhibits renal protective effects by activating the TGR5 receptor and inhibiting ferroptosis in renal tubular epithelial cells; and acts as a TGR5 agonist and FXR antagonist to counteract obesity and insulin resistance.
体外研究
(In Vitro)

Notoginsenoside Ft1 (0-10 μM,0-48 小时) 显著促进 HUVEC 增殖和迁移,促进细胞周期由 G1 期向 S 期转变,显著促进 HUVEC 管状结构的形成,并通过抑制 PI3K/AKT/mTOR 通路和 Raf/MEK/ERK 通路促进 VEGF 的表达和分泌。
Notoginsenoside Ft1 (0-250 μM) 在中以剂量依赖性方式促进大鼠血小板聚集 (EC50 = 56.42 μM),并在人血浆 (240 μg/mL,5 分钟) 和大鼠血浆 (80 μg/mL,5 分钟) 中均表现出全面的促凝作用,影响外源性及自身凝血途径。
Notoginsenoside Ft1 (56.4 μM) 可诱导血小板和 P2Y12-HEK293 细胞内 Ca²⁺ 升高,显著抑制 cAMP 的产生,并诱导 PI3K 和 Akt 的磷酸化。
Notoginsenoside Ft1 (1 nM-10 mM,30 分钟) 可刺激大鼠肠系膜动脉内皮细胞 GR 和 ERb,随后激活 PI3K/Akt 和 ERK1/2 通路,导致 eNOS 磷酸化和 NO 释放,进而激活血管平滑肌细胞中的可溶性鸟苷酸环化酶,导致血管扩张。
Notoginsenoside Ft1 (0.1-100 μM,24 小时) 可抑制 SH-SY5Y 细胞 (IC50 = 45 μM),导致细胞周期停滞并诱导细胞凋亡,涉及调节 p38 MAPK 和 ERK1/2 通路。
Notoginsenoside Ft1 (0.1-10 μM,0.5-24 小时) 显著激活 TGR5 的荧光素酶活性,增加 Tgr5-HEK293 细胞中的 cAMP 水平,并促进 NCI-H716 细胞中 GLP-1 的分泌。
Notoginsenoside Ft1 (10 μM,24 小时) 显著抑制 Caco-2 细胞中的 FXR 靶基因,并抑制 GW4064 (MS-L87730) 诱导的 HEK293T 细胞中的 FXR 活性细胞。
Notoginsenoside Ft1 (10 μM,24 小时) 对 HepG2 (IC50 = 46.3 μM)、Huh7 (IC50 = 35.2 μM) 和 PLC/PRF/5 (IC50 = 58.9 μM) 细胞有抑制作用,但对 THLE-2 (IC50 = 82.2 μM) 细胞无抑制作用。
Notoginsenoside Ft1 (12.5-50 μM,12-24 小时) 通过抑制 PI3K/AKT/mTOR 通路诱导细胞凋亡,并通过激活 HepG2 细胞中的 TFEB 促进溶酶体细胞死亡。
Notoginsenoside Ft1 (0-100 μM,24 小时-14 天) 可抑制 MC38、CT26、HT29 细胞的生长,IC50 分别为 32.87、30.75 和 27.59 μM,抑制 MC38 细胞的克隆形成,显著抑制 MC38 和 CT26 细胞的迁移能力,抑制集落形成数量。
Notoginsenoside Ft1 (5 μM,24 小时) 成功抑制了 HK2 细胞中的铁死亡模型,表现为细胞活力增加、抑制 ROS 积累、线粒体功能障碍改善以及铁死亡标志蛋白的表达改变。

Cell Cycle Analysis

Cell Line: HUVECs
Concentration: 10 μM
Incubation Time: 0, 3, 6, 12, 16, 24 h
Result: Increased the proportion of cells in the S phase and decreased the proportion of cells in the G1 phase.

Cell Migration Assay

Cell Line: HUVECs
Concentration: 0, 0.5, 1, 2.5, 5 and 10 μM
Incubation Time: 24 h
Result: Promoted HUVECs migration in a dose-dependent manner.

Western Blot Analysis

Cell Line: HUVECs
Concentration: 10 μM
Incubation Time: 0, 15, 30 min, 1, 2, 4, 8, 12 and 24 h
Result: Promoted PI3K, AKT, mTOR, c-Raf, MEK1/2 and ERK1/2 phosphorylation.
Promoted HIF-1α translocation from the cytoplasm to the nucleus in a time-dependent manner.

Western Blot Analysis

Cell Line: Rat mesenteric arteries
Concentration: 100 μM
Incubation Time: 30 min
Result: Significantly increased p-eNOS, but no significant change in total eNOS expression; eNOS expression was almost undetectable in the endothelial removal group.
Increased Akt phosphorylation and ERK1/2 phosphorylation.
Increased the levels of p-GR (Ser211) and p-ERβ (Ser87) in the endothelial layer.

Cell Cycle Analysis

Cell Line: SH-SY5Y cells
Concentration: 22.5, 45 and 67.5 μM
Incubation Time: 24 h
Result: Caused arrest at the S phase and G2/M phase22.5-45 μM.
Only causes G2/M phase arrest at 67.5 μM.

Apoptosis Analysis

Cell Line: SH-SY5Y cells
Concentration: 45 and 67.5 μM
Incubation Time: 24 h
Result: Showed nuclear enrichment and fragmentation.
showed that the rate of early apoptosis increased from 13.6% to 48.9%.

Western Blot Analysis

Cell Line: SH-SY5Y cells
Concentration: 22.5, 45 and 67.5 μM
Incubation Time: 24 h
Result: Increased cleaved caspase-3 and decreased Bcl-2.
Increased p-p53, p21 and cyclin B1.
Increased p-ERK1/2, p-JNK and p-p38, decreased p-Jak2 and p-PI3K.

Apoptosis Analysis

Cell Line: HepG2 and Huh7 cells
Concentration: 12.5, 25 and 50 μM
Incubation Time: 24 h
Result: Increased significantly the proportion of early and late apoptotic cells.
Increased expression of cleaved PARP, caspase-9, caspase-8, and caspase-3.
体内研究
(In Vivo)

Notoginsenoside Ft1 (1-25 μM 用于 Matrigel 栓塞试验,0.25-25 mg/kg 用于耳部伤口愈合试验,腹腔注射,单次给药和隔日给药,共 28 天) 可促进小鼠 Matrigel 栓塞中血管的形成和伤口愈合。
Notoginsenoside Ft1 (1.25 mg/kg,静脉注射,单次给药) 可显著增加 Wistar 大鼠的血栓形成并缩短出血时间。
Notoginsenoside Ft1 (50-100 mg/100 g 饮食,口服,共 6 周) 可改善肥胖症,通过激活 Tgr5 改善高脂饮食 (HFD) 小鼠的血糖紊乱,并通过拮抗 FXR 增强肝脏胆汁酸 (BA) 的合成。
Notoginsenoside Ft1 (25-50 mg/kg,口服,每日一次,连续 3 周) 在 HepG2 异种移植瘤小鼠模型中显示出抗癌作用。
Notoginsenoside Ft1 (10-30 mg/kg,腹腔注射,每日一次,连续 24 天) 显著抑制结直肠癌 (CRC) 皮下肿瘤形成,并提高荷瘤小鼠 CD8+ T 细胞比例,从而抑制肿瘤生长。
Notoginsenoside Ft1 可通过激活 JUN 信号通路控制小鼠血糖,减少肾小管损伤,并干预肾脏铁死亡的发生。

Animal Model: Matrigel plug assay established in Balb/c nude mice (8 weeks old)
Dosage: 1, 5 and 25 μM with Heparin (MS-E36645) in Matrigel
Administration: Intraperitoneal injection (i.p.), single dose
Result: Formed of a functional vasculature inside the Matrigel.
Increased the hemoglobin content in a dose-dependent manner.
Revealed a dose-dependent increase in staining with the blood vessel endothelial cell marker CD-31 Matrigels with more enlarged and more blood vessels.
Animal Model: Ear wound healing assay established in Balb/c nude mice (8 weeks old)
Dosage: 0.25 mg/kg, 2.5 mg/kg or 25 mg/kg
Administration: Intraperitoneal injection (i.p.), every other day for 28 days
Result: Significantly reduced the diameter of the wound, and more new blood vessels could be observed at the wound edge.
Significantly upregulated the expression of VEGF mRNA.
No significant difference in the weight changes of the mice in each group.
Animal Model: Diet-induced obesity model established in Tgr5 -/- mice, Cyp27a1-/- mice and wild-type mice
Dosage: 50 and 100 mg/100 g diet
Administration: Oral administration (p.o.) with diet, for 6 weeks
Result: Reduced the weight gain of mice, significantly decreased the diameter of fat cells, and reduced the deposition of lipid droplets in the liver.
Reduced fasting metabolic parameters, lowered blood sugar, improved insulin resistance index (HOMA-IR) and enhanced insulin sensitivity.
Increased energy digestion and improved cold tolerance.
Upregulated Cyp7a1 and Cyp27a1 mRNA in the liver and downregulated Fgf15 mRNA in the ileum.
Increased Ucp1 expression in BAT and iWAT, and upregulated genes such as Pgc1a and Prdm16.
Increased PKA substrate phosphorylation, HSL phosphorylation, and serum glycerol levels.
Animal Model: HepG2 xenograft tumor model established in adult male mice
Dosage: 25 and 50 mg/kg
Administration: Oral administration (p.o.), once daily for 3 weeks
Result: Significantly reduced tumor volume and weight.
No significant weight loss caused, and no obvious pathological changes found in major organs.
Reduced KRAS, ERK1/2, c-Fos, and JUND proteins levels.
Animal Model: MC38 or CT26 -induced CRC model established in C57BL/6J and Balb/c mice, male, SPF grade, aged 6-8 weeks, and weighing 18 g
Dosage: 10 and 30 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 24 days
Result: Significantly inhibited tumor growth at 30 mg/kg.
No obvious weight loss, no obvious pathological changes in major organs such as liver and kidney.
Significantly increased the proportion of CD8+ T cells in tumors.
性状 固体
颜色 White to off-white

化学信息

分子量 917.13
分子式 C47H80O17
CAS No. 155683-00-4
别名 三七皂苷FT1

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (10.9 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.18 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (109.04 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.0904 mL5.4518 mL10.9036 mL27.2589 mL
5 mM0.2181 mL1.0904 mL2.1807 mL5.4518 mL
10 mM0.1090 mL0.5452 mL1.0904 mL2.7259 mL
15 mM0.0727 mL0.3635 mL0.7269 mL1.8173 mL
20 mM0.0545 mL0.2726 mL0.5452 mL1.3629 mL
25 mM0.0436 mL0.2181 mL0.4361 mL1.0904 mL
30 mM0.0363 mL0.1817 mL0.3635 mL0.9086 mL
40 mM0.0273 mL0.1363 mL0.2726 mL0.6815 mL
50 mM0.0218 mL0.1090 mL0.2181 mL0.5452 mL
60 mM0.0182 mL0.0909 mL0.1817 mL0.4543 mL
80 mM0.0136 mL0.0681 mL0.1363 mL0.3407 mL
100 mM0.0109 mL0.0545 mL0.1090 mL0.2726 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

三七皂甙 Ft1 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础